Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.
Author(s): Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H
Affiliation(s): Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. giovanni.schifitto@ctcc.rochester.edu
Publication date & source: 2006-03-28, Neurology., 66(6):919-21. Epub 2006 Mar 1.
Publication type: Randomized Controlled Trial
In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.
|